Mycobacterium avium complex (MAC) infections occur frequently in AIDS patients
. The clinical management of these infections is difficult because of the intrinsic resistance of MAC to most antimicrobial agents which is in part due to their impermeability (13, 26) . Moreover, when an antimicrobial agent lacks the ability to penetrate into phagocytes, in which MAC can proliferate, its efficacy is also reduced (25, 27) . M. avium, especially serovar 4, is isolated from AIDS patients in the United States more frequently than M. intracellulare (12, 14, 36) , whereas they are isolated in nearly equal rates from non-AIDS patients (14, 23) . Therefore, it is preferable to use M. avium rather than M. intracellulare for estimating the therapeutic efficacy of a drug against MAC infections in AIDS patients. Furthermore, it was demonstrated that avian M. avium is highly virulent in birds, pigs, and rabbits (1, 7, 31) and, when a large inoculum is administered intravenously in rabbits, causes a Yersin type infection (1, 33, 34) , a peculiar type of experimental bovine tuberculosis characterized by a very rapid course, enlargement of the spleen and liver, and septic infection (35) . Aspects of this infection resemble certain features of disseminated MAC infection in AIDS patients (14, 15, 22, 36) , especially in terms of bacteremia and rapid bacterial growth in multiple organs, which result in acute progression of disease and subsequent death of the host. Therefore, the experimental rabbit infection system using M. avium isolated from avian sources may be suitable for evaluating the therapeutic activities of a given drug against MAC infections in AIDS patients. Since there is synergy between rifamycins and other antituberculosis drugs, such as ethambutol (16, 17) , against MAC in vitro, * Corresponding author. rifamycins seem to be promising drugs for the clinical control of MAC infections in AIDS patients (3, 26) . Previously, we found that a group of new rifamycin derivatives, benzoxazinorifamycins (KRMs) (KANEKA Corporation, Hyogo, Japan), had excellent in vitro antimycobacterial activities, especially against MAC (30) . In the KRM series, KRM-1648 in particular exhibited excellent therapeutic activity against M. intracellulare infection induced in mice (32) . This was also the case for M. intracellulare infection induced in NK cell-deficient beige mice (28) (as a plausible model for AIDS-associated MAC infection), in which a much higher progressive state of gross lesions and bacterial loads at the sites of infection was observed (10, 11) . In this study, the therapeutic efficacy of KRM-1648 was assessed against disseminated infection induced in rabbits by M. avium isolated from an avian source. 25 x 108 CFU/ml), and used as an inoculum for experimental infection. New Zealand White rabbits, injected intravenously with 1 ml of the inoculum, were given KRM-1648, RMP, and CAM finely emulsified in 2.5% gum arabic-1% Tween 80 solution by gavage, once daily six times per week, until the end of the experiment. The therapeutic efficacy of the test drug was determined on the basis of changes in body weight, survival time, mortality rate, amount of serum bilirubin, and bacterial load in the blood and at the sites of infection. The number of CFU in the visceral organs and blood were determined as follows. The tissue (i.e., lung, liver, spleen, and kidney) homogenates in 5 ml of distilled water, prepared using a glass homogenizer, were decontaminated with 0.5 ml of 2% NaOH for 20 s. This was followed by immediate neutralization with 0.5 N HCl prior to serial 10-fold dilution with distilled water. One milliliter of blood was also treated with 0.1 ml of NaOH for 20 s, which was immediately followed by neutralization, and a serial 10-fold dilution with distilled water was prepared, unless otherwise specified. A 0.1-ml portion of each resulting dilution was inoculated onto a 7H11 agar plate and cultivated at 37°C in a CO2 incubator (5% C02-95% humidified air) for 2 weeks before CFU counting, unless otherwise specified.
MATERIALS AND METHODS

Organism
Measurement of serum bilirubin level. Table 1 , a high bacterial load was observed in the lungs, liver, spleen, and kidneys in untreated rabbits at the time of death. These features, i.e., rapid progression of the infection resulting in death of the host in the early phase of infection, obvious bacteremia, and rapid bacterial growth at the site of infection, indicate that the present experimental M. avium infection bears a considerable resemblance to disseminated MAC infection in AIDS patients.
As shown in Table 1 , all infected rabbits survived when KRM-1648 was administered at a dose of 25 or 50 mg/kg but not 10 mg/kg. Decrease in body weight in the early phase of infection was noted in all test animals, but animals treated with KRM-1648 at a dose of 25 or 50 mg/kg recovered normal body weight thereafter. As shown in Fig. 1B , bacteremia induced by M. avium infection was retarded after a 10-mg/kg dose of KRM-1648 and was completely suppressed by a dose of 25 or 50 mg/kg. The increase in serum bilirubin seen in the untreated rabbits during the first 2 weeks after infection was markedly suppressed by KRM-1648 treatment at 25 or 50 In contrast, the alveoli of the lungs of a rabbit (Fig. 2b ) which survived because of the KRM-1648 treatment were almost intact, and there were no typical granulomatous lesions, although some infiltration of lymphocytes and small numbers of epithelioid cells were seen (Fig. 2B) . Granulomatous foci seen in untreated rabbits were substantially abolished by KRM-1648 treatment (Fig. 2B) . Similar histopathological features were also seen in the spleens and livers of the KRM-1648-treated rabbits. Therefore, the rabbits which survived because of KRM-1648 treatment were substantially free from the microscopic lesions and inflammatory reactions associated with M. avium infection.
Therapeutic efficacy of KRM-1648 against M. avium infection induced by different inoculum sizes. As shown in Table 3 , rabbits were given M. avium N-425 at various doses ranging from 0.1 mg (wet weight) (4.9 x 107 CFU per rabbit) to 5 mg (wet weight) (2.5 x 109 CFU per rabbit). The survival time for untreated rabbits varied from 19 to 169 days; the survival time for rabbits infected with 4.9 x 108 or 2.5 x 109 CFU of the organisms was 19 to 20 days, but when the inoculum size was lowered to 4.9 x 107 per rabbit, it was considerably prolonged (169 days). The bacterial loads in the visceral organs were markedly lower in rabbits that died 169 days after infection with the small inoculum than in animals dead 20 days after infection with a large inoculum.
One of the two rabbits infected with 2.5 x 109 bacteria and given 50 mg of KRM-1648 per kg died 15 days after infection, but the other survived until the sacrifice (day 63). There was a marked decrease in body weight in the early phase of infection, regardless of KRM-1648 treatment. However, because of the KRM-1648 treatment, the surviving rabbits recovered normal body weight. Enlargement of the spleen was markedly suppressed in the rabbits which survived because of drug administration (data not shown). Almost complete bacterial elimination from all the visceral organs and from the blood of the survivors was observed (Table 3) .
Comparative therapeutic efficacies of KRM-1648, RMP, and CAM. The therapeutic efficacy of KRM-1648 against M. avium N-425 infection was compared with those of RMP and CAM (a newly developed macrolide with potent in vitro and in vivo antimycobacterial activities [6, 9, 19] ) given at a dose of 25 mg/kg. As shown in Fig. 3A , all three agents increased the survival rate of infected rabbits from that of untreated rabbits. The efficacy was in the following order: KRM-1648 > CAM > RMP. The average survival time of animals given KRM-1648 (surviving animals were killed at 30 days) was 26.5 + 6.1 (mean + standard deviation) days and was significantly longer than that of untreated rabbits (14.5 ± 0.5 days) (P < 0.05; Student's t test). Moreover, KRM-1648-treated rabbits lived longer than both RMP-treated (18.5 + 0.9 days) and CAM-treated (21.3 ± 5.3 days) rabbits, although the difference was not significant. Although, similar losses in body weight were seen in the untreated rabbits and those treated with KRM-1648, CAM, and RMP during the first 3 weeks after infection, rapid body weight recovery was observed thereafter only in the KRM-1648-treated rabbits (Fig. 3B) . Table 4 summarizes the bacterial loads in the visceral organs and the blood and serum bilirubin levels of the rabbits either at the time of death or at 30 days postinfection. Surviving rabbits receiving KRM-1648 treatment showed bacterial loads in all tested visceral organs (lungs, liver, spleen, and kidneys) that were markedly lower than those in the rabbits that died, including the untreated or drug-administered animals; the degree of bacterial load reduction was statistically significant (P, <0.005 to <0.05). Among surviving animals, the bacterial loads in KRM-1648-treated rabbits (n = 3) were 2 to 3 log units lower than those in the CAM-treated rabbit (n = 1). This may indicate that EMORI ET AL. 1648 allowed a more rapid recovery in the infected rabbits than CAM did. Among the animals that died, KRM-1648-treated (n = 1) and RMP-treated (n = 4) rabbits had visceral bacterial loads 1 to 3 log units lower than those in untreated control rabbits. In contrast, such an obvious decrease in the bacterial load was not noted in CAM-treated rabbits. This may suggest some differences in the modes of action of macrolides and rifamycins, especially during the early phase of M. avium infection. It should be emphasized that the bacteremia that was seen in all dead rabbits regardless of drug administration was completely suppressed in the animals that survived because of administration of KRM-1648 or CAM (Table 4) . Furthermore, the marked increase in serum bilirubin levels seen in the nonsurviving rabbits of the four regimens was potently suppressed in animals that als to investigate the therapeutic efficacy of KRM-1648 in the control of M. avium infections in AIDS patients are urgently needed. The findings from the present and previous studies of experimental MAC infections induced in mice and rabbits are encouraging, and clinical studies should be conducted on this new rifamycin derivative.
Additionally, as shown in Fig. 2 , well-developed granulomatous lesions with well-formed epithelioid cells were observed in the lung sections of M. avium-infected rabbits by using hematoxylin and eosin staining, indicating the existence of CD4+ Th cells actively producing macrophageactivating lymphokines (5, 20, 21) , levels of which are lowered in AIDS patients. Thus, the T-cell-mediated defense mechanism in rabbits is considerably different than that in AIDS patients. In a murine model of M. intracellulare infection, the behavior of the organisms in the visceral organs of T-cell-deficient athymic nude mice was almost the same as that seen in euthymic mice during the first 4 weeks postinfection (29) , although subsequent bacterial growth was slightly faster in athymic mice than in euthymic mice. Therefore, in murine MAC infection, T cells may not play such a large role in the expression of host resistance, although they are still important in preventing the progression of the infection to a terminal state (29) . In contrast, NK cells seem to be involved in the establishment of host resistance to MAC, since much more severe infections could be induced in NK-deficient beige mice than in normal mice (10, 11) . These profiles may indicate the importance of macrophage and NK cell lineages in host resistance against MAC infection. Elucidation of the status and participation of various immunocompetent cells, including CD4+ and CD8+ T cells, macrophages, and NK cells, in M. avium infection in rabbits warrants further research in order to accurately evaluate the present rabbit experimental infection system as a model for AIDS-associated MAC infections.
